IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

GENZYME CORPORATION and AVENTIS INC.,	)	
Plaintiffs,	)	
v.	)	
	)	C.A. No. 21-1736-RGA
NOVARTIS GENE THERAPIES, INC., NOVARTIS PHARMACEUTICALS CORPORATION,	)	
Defendants.	)	

STIPULATION AND [PROPOSED] ORDER TO AMEND CASE SCHEDULE

IT IS HEREBY STIPULATED AND AGREED by and between the parties, subject to the approval of the Court, that the case schedule is modified as follows:

Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation
IPR2023-00608 (US 9,051,542)
Exhibit 2010

EVENT	Previous Deadline	Amended Deadline
Hearing on Claim Construction	February 8, 2023 (cancelled)	TBD
Completion of Fact Discovery	March 31, 2023	June 30, 2023
Opening Disclosure of Expert Testimony	May 18, 2023	August 4, 2023
Rebuttal Disclosure of Expert Testimony	June 29, 2023	September 12, 2023
Any Reply Disclosure of Expert Testimony	July 27, 2023	October 3, 2023
Completion of Expert Discovery	August 31, 2023	October 27, 2023
Discovery Cutoff	See Fact and Expert Discovery Completion Dates Above	See Fact and Expert Discovery Completion Dates Above
Case Dispositive Motions	September 30, 2023	November 10, 2023
Responses to Case Dispositive Motions	October 21, 2023	November 30, 2023
Replies to Case Dispositive Motions	November 4, 2023	December 12, 2023
Pretrial Conference	March 8, 2024 at 8:30 am	March 8, 2024 at 8:30 am
5-Day Jury Trial	March 25, 2024	March 25, 2024

Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation
IPR2023-00608 (US 9,051,542)
Exhibit 2010

Dated: March 7, 2023

WILKS LAW, LLC

/s/ David E. Wilks
David E. Wilks (Del. Bar #2793)
Scott B. Czerwonka (Del. Bar #4844)
4250 Lancaster Pike, Suite 200
Wilmington, DE 19085
(302) 225-0858
dwilks@wilks.law
sczerwonka@wilks.law

OF COUNSEL:

Paul H. Berghoff
Joshua R. Rich
George T. Lyons, III
Bryan G. Helwig
Alexandra E. MacKenzie
Daniel Gonzalez, Jr.
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 South Wacker Drive
Chicago, IL 60606
(312) 913-0001
berghoff@mbhb.com
rich@mbhb.com
lyons@mbhb.com
helwig@mbhb.com
mackenzie@mbhb.com
gonzalez@mbhb.com

Attorneys for Plaintiffs Genzyme Corporation and Aventis Inc.

MCCARTER & ENGLISH, LLP

/s/ Daniel M. Silver
Daniel M. Silver (#4758)
Alexandra M. Joyce (#6423)
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, Delaware 19801
(302) 984-6300
dsilver@mccarter.com
ajoyce@mccarter.com

OF COUNSEL:

John Livingstone
M. David Weingarten, Ph.D.
Megan Meyers
Shannon Patrick
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP
271 17th Street, NW, Suite 1400
Atlanta, GA 30363-6209
(404) 653.6449
John.Livingstone@finnegan.com
david.weingarten@finnegan.com
Megan.meyers@finnegan.com
Shannon.patrick@finnegan.com

Amanda Murphy, Ph.D.
FINNEGAN, HENDERSON, FARBOW, GARRETT & DUNNER LLP
1 London Bridge
London, United Kingdom SEI 9BG
Amanda.murphy@finnegan.com

Cora Holt
Christopher W. Weber, Ph.D.
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP
901 New York Avenue, NW
Washington, DC 20001-4413
(202) 408.4153
Cora.Holt@finnegan.com
christopher.weber@finnegan.com

Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation
IPR2023-00608 (US 9,051,542)
Exhibit 2010

Attorneys for Defendants Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corp., and Novartis AG

SO ORDERED this 7th day of March, 2023.

/s/ Richard G. Andrews
United States District Court Judge

Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation
IPR2023-00608 (US 9,051,542)
Exhibit 2010